130 related articles for article (PubMed ID: 7933214)
1. Suramin inhibits proliferation and DNA synthesis in transitional carcinoma cell lines.
Walther MM; Trahan EE; Cooper M; Venzon D; Linehan WM
J Urol; 1994 Nov; 152(5 Pt 1):1599-602. PubMed ID: 7933214
[TBL] [Abstract][Full Text] [Related]
2. A phase I study of intravesical suramin for the treatment of superficial transitional cell carcinoma of the bladder.
Uchio EM; Linehan WM; Figg WD; Walther MM
J Urol; 2003 Jan; 169(1):357-60. PubMed ID: 12478189
[TBL] [Abstract][Full Text] [Related]
3. Human bladder cancer invasion model using rat bladder in vitro and its use to test mechanisms and therapeutic inhibitors of invasion.
Fujiyama C; Jones A; Fuggle S; Bicknell R; Cranston D; Harris AL
Br J Cancer; 2001 Feb; 84(4):558-64. PubMed ID: 11207054
[TBL] [Abstract][Full Text] [Related]
4. This month in Investigative Urology. A commentary on suramin demonstrates in vitro toxicity against transitional cell carcinoma cell lines and exposure to alkyllysophospholipids inhibits in vitro invasion of transitional cell carcinoma.
Droller MJ
J Urol; 1994 Nov; 152(5 Pt 1):1356-7. PubMed ID: 7933161
[No Abstract] [Full Text] [Related]
5. Intravesical suramin: a novel agent for the treatment of superficial transitional-cell carcinoma of the bladder.
Walther MM; Figg WD; Linehan WM
World J Urol; 1996; 14 Suppl 1():S8-11. PubMed ID: 8738403
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of human transitional cell carcinoma in vitro proliferation by fluoroquinolone antibiotics.
Seay TM; Peretsman SJ; Dixon PS
J Urol; 1996 Feb; 155(2):757-62. PubMed ID: 8558720
[TBL] [Abstract][Full Text] [Related]
7. Suramin inhibits growth factor binding and proliferation by urothelial carcinoma cell cultures.
Gansler T; Vaghmar N; Olson JJ; Graham SD
J Urol; 1992 Sep; 148(3):910-4. PubMed ID: 1512858
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of growth stimulation by suramin in non-small-cell lung cancer cell lines.
Lokshin A; Peng X; Campbell PG; Barsouk A; Levitt ML
Cancer Chemother Pharmacol; 1999; 43(4):341-7. PubMed ID: 10071987
[TBL] [Abstract][Full Text] [Related]
9. Role of suramin as an IL-1 inhibitor in suppression of acute myelogenous leukemia progenitor proliferation.
Estrov Z; Talpaz M; Estey EH; Strassmann G
Exp Hematol; 1995 Sep; 23(10):1080-7. PubMed ID: 7544738
[TBL] [Abstract][Full Text] [Related]
10. Suramin inhibits growth and transforming growth factor-beta 1 (TGF-beta 1) binding in osteosarcoma cell lines.
Kloen P; Jennings CL; Gebhardt MC; Springfield DS; Mankin HJ
Eur J Cancer; 1994; 30A(5):678-82. PubMed ID: 8080687
[TBL] [Abstract][Full Text] [Related]
11. Suramin affects DNA synthesis in HeLa cells by inhibition of DNA polymerases.
Jindal HK; Anderson CW; Davis RG; Vishwanatha JK
Cancer Res; 1990 Dec; 50(24):7754-7. PubMed ID: 2174730
[TBL] [Abstract][Full Text] [Related]
12. Suramin interrupts androgen-inducible autocrine loop involving heparin binding growth factor in mouse mammary cancer (Shionogi carcinoma 115) cells.
Kasayama S; Saito H; Kouhara H; Sumitani S; Sato B
J Cell Physiol; 1993 Feb; 154(2):254-61. PubMed ID: 7678839
[TBL] [Abstract][Full Text] [Related]
13. Phase I trial of intravesical Suramin in recurrent superficial transitional cell bladder carcinoma.
Ord JJ; Streeter E; Jones A; Le Monnier K; Cranston D; Crew J; Joel SP; Rogers MA; Banks RE; Roberts IS; Harris AL
Br J Cancer; 2005 Jun; 92(12):2140-7. PubMed ID: 15928663
[TBL] [Abstract][Full Text] [Related]
14. Effect of suramin on the mitogenic response of the human prostate carcinoma cell line PC-3.
Ewing MW; Liu SC; Gnarra JR; Walther MM; Meyers CE; Linehan WM
Cancer; 1993 Feb; 71(3 Suppl):1151-8. PubMed ID: 8428338
[TBL] [Abstract][Full Text] [Related]
15. The anti-proliferative effect of suramin towards tamoxifen-sensitive and resistant human breast cancer cell lines in relation to expression of receptors for epidermal growth factor and insulin-like growth factor-I: growth stimulation in the presence of tamoxifen.
Boylan M; van den Berg HW; Lynch M
Ann Oncol; 1998 Feb; 9(2):205-11. PubMed ID: 9553667
[TBL] [Abstract][Full Text] [Related]
16. Dexamethasone and suramin inhibit cell proliferation and interleukin-6-mediated immunoglobulin secretion in human lymphoid and multiple myeloma cell lines.
Shiao RT; Miglietta L; Khera SY; Wolfson A; Freter CE
Leuk Lymphoma; 1995 May; 17(5-6):485-94. PubMed ID: 7549842
[TBL] [Abstract][Full Text] [Related]
17. The effects of coumarin and suramin on the growth of malignant renal and prostatic cell lines.
Myers RB; Parker M; Grizzle WE
J Cancer Res Clin Oncol; 1994; 120 Suppl():S11-3. PubMed ID: 8132694
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity of common antibiotics against superficial bladder cancer.
Kamat AM; Lamm DL
Urology; 2004 Mar; 63(3):457-60. PubMed ID: 15028437
[TBL] [Abstract][Full Text] [Related]
19. In vitro effect of suramin on lung tumour cells.
Mórocz IA; Lauber B; Schmitter D; Stahel RA
Eur J Cancer; 1993; 29A(2):245-7. PubMed ID: 8422289
[TBL] [Abstract][Full Text] [Related]
20. Suramin: prototype of a new generation of antitumor compounds.
La Rocca RV; Stein CA; Myers CE
Cancer Cells; 1990 Apr; 2(4):106-15. PubMed ID: 2202382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
